Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Under Armour Inc Class A — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B), while Under Armour Inc Class A trades at $4.79 (market cap $2.03B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.6× Under Armour Inc Class A's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Under Armour Inc Class A for 99 Days on average.
| SYRE | UAA | |
|---|---|---|
Market Cap | $7.35B | $2.03B |
Volume | 1,624,631 | 7,140,862 |
Sector | Health | Consumer Cyclical |
52-Week High | $108.92 | $8.14 |
52-Week Low | $22.18 | $4.17 |
Typical Hold Time | 0 Days | 99 Days |
Enterprise Value | $6.35B | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Under Armour (UAA) trades at $4.90, down 0.61% amid ongoing revenue challenges but shows technical bullish signals. The company reported mixed Q2 2026 results with an earnings beat but faces declining revenues and negative net margins. Recent news highlights Under Armour's strategic focus on product simplification and international growth while navigating North American weakness. Technical indicators show bullish moving averages with RSI suggesting potential overbought conditions near-term.
The outlook remains challenging with revenue declines projected through 2026, though cost discipline supports margin recovery. Investment opportunity exists if the brand transformation succeeds, but risks include persistent demand weakness and competitive pressures. Analyst consensus is mixed with a $5.79 price target representing 18% upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
